Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT0JLSD)

DTT Name Multidrug resistance protein (MDR)
Synonyms P-glycoprotein
Gene Name NO-GeName
DTT Type
Successful target
 [1]
Related Disease
Nausea/vomiting [ICD-11: MD90]
BioChemical Class
ABC transporter
UniProt ID
NOUNIPROTAC
TTD ID
T16422

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Benzquinamide DMU4D5Y Nausea MD90 Approved [1]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
MM36 DM6VPIO Atopic dermatitis EA80 Phase 2 [2]
Ortataxel DM1EK5D Solid tumour/cancer 2A00-2F9Z Phase 2 [3], [4]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valspodar DMXRU9M Acute myeloid leukaemia 2A60 Discontinued in Phase 3 [5]
------------------------------------------------------------------------------------
3 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Chemosensitizers DMYSG9J Discovery agent N.A. Investigative [6]
KP772 DMUZSJ2 Discovery agent N.A. Investigative [2]
WK-X-34 DMX0ZBC Discovery agent N.A. Investigative [2]
------------------------------------------------------------------------------------

References

1 Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65.
2 Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
3 Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
4 Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer. 2008 Nov 18;99(10):1579-85.
5 Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15. Jpn J Cancer Res. 2001 Oct;92(10):1116-26.
6 P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000 Jul;1(1):85-99.